TheStreet Search RSS Feed: Helene Meisler

5 Buy-Rated Dividend Stocks: WMB, MIC, OHI, TCP, MPW

Tue, 18 Jun 2013 11:30:48 EDT

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

TheStreet Ratings' stock model projects a stock's total return potential over a 12-month period including both price appreciation and dividends. Our Buy, Hold or Sell ratings designate how we expect these stocks to perform against a general benchmark of the equities market and interest rates. While plenty of high-yield opportunities exist, investors must always consider the safety of their dividend and the total return potential of their investment. It is not uncommon for a struggling company to suspend high-yielding dividends and subsequently result in precipitous share price declines. TheStreet Ratings' stock rating model views dividends favorably, but not so much that other factors are disregarded. Our model gauges the relationship between risk and reward in several ways, including: the pricing drawdown as compared to potential profit volatility, i.e. how much one is willing to risk in order to earn profits?; the level of acceptable volatility for highly performing stocks; the current valuation as compared to projected earnings growth; and the financial strength of the underlying company as compared to its stock's valuation as compared to its stock's performance. These and many more derived observations are then combined, ranked, weighted, and scenario-tested to create a more complete analysis. The result is a systematic and disciplined method of selecting stocks. As always, stock ratings should not be treated as gospel — rather, use them as a starting point for your own research. The following pages contain our analysis of 5 stocks with substantial yields, that ultimately, we have rated "Buy."...

Click to view a price quote on WMB.

Click to research the Energy industry.

Enduro Royalty Trust Announces Monthly Cash Distribution

Tue, 18 Jun 2013 09:15:00 EDT

Enduro Royalty Trust (NYSE: NDRO) (the “Trust”) announced today a cash distribution to the holders of its units of beneficial interest of $0.128817 per unit, payable on July 15, 2013, to unitholders of record on June 28, 2013. The distribution primarily represents oil production during the month of March 2013 and natural gas production during February 2013.

The following table displays underlying oil and natural gas sales volumes and average prices attributable to the current and prior month distributions. Underlying Sales Volumes Average Price Oil Natural Gas Oil Natural Gas (Bbls) (Mcf) (per Bbl) (per Mcf) Current Month 75,917 612,661 $ 86.06 $ 3.38 Prior Month 68,813 699,021 $ 79.77 $ 3.39 ...

Click to view a price quote on NDRO.

Click to research the Energy industry.

'Mountain Astrologer' Magazine Publishes Investigative Feature On History Of Monsanto And Genetic Engineering Of Food

Tue, 18 Jun 2013 08:20:00 EDT

KINGSTON, N.Y., June 18, 2013 /PRNewswire/ -- How did Monsanto become so powerful? How is such a relatively small company so influential?

These are among the questions asked in "In Through the Out Door: The Cosmic Signature of Monsanto and GMOs," an investigative feature written by Eric Francis Coppolino, editor of Planet Waves. ...

Gilead Sciences Inc (GILD): Today's Featured Drugs Laggard

Mon, 17 Jun 2013 17:01:07 EDT

Gilead (GILD) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole was unchanged today. By the end of trading, Gilead fell $1.20 (-2.3%) to $51.03 on average volume. Throughout the day, 10,014,910 shares of Gilead exchanged hands as compared to its average daily volume of 12,338,500 shares. The stock ranged in price between $50.82-$53.26 after having opened the day at $52.77 as compared to the previous trading day's close of $52.23. Other companies within the Drugs industry that declined today were: Amicus Therapeutics (FOLD), down 20.4%, Oramed Pharmaceuticals (ORMP), down 19.1%, Senesco Technologies (SNTI), down 12.6% and Oxygen Biotherapeutics (OXBT), down 11.2%.EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass...

Click to view a price quote on GILD.

Click to research the Drugs industry.

AFC Enterprises, Inc. Chief Executive Officer Adopts New 10b5-1 Trading Plan

Mon, 17 Jun 2013 17:00:00 EDT

AFC Enterprises, Inc. (NASDAQ: AFCE) today announced that Cheryl Bachelder, Chief Executive Officer, has established a new trading plan in accordance with Rule 10b5-1 of the Securities Exchange Act. Rule 10b5-1 permits individuals who are not then in possession of material non-public information to establish pre-arranged plans to buy or sell stock. The rule allows individuals to buy or sell shares of stock at a specific price in the future, regardless of any subsequent material non-public information.

This plan was adopted to enable Ms. Bachelder to continue to exercise and sell a portion of her AFCE stock options over time as part of Ms. Bachelder’s long-term strategy for asset diversification and tax management. Utilizing this type of plan, Ms. Bachelder can gradually diversify her investment portfolio, spreading stock trades out over an extended period of time, reducing market impact. If all sales in this plan are transacted, Ms. Bachelder’s holdings will continue to remain in excess of the company’s stock holding policy of 4 times her base salary. ...

Click to view a price quote on AFCE.

Click to research the Leisure industry.

3 Sell-Rated Dividend Stocks: AMTG, OAK, ECA

Mon, 17 Jun 2013 11:30:48 EDT

TheStreet Ratings' stock model projects a stock's total return potential over a 12-month period including both price appreciation and dividends. Our Buy, Hold or Sell ratings designate how we expect these stocks to perform against a general benchmark of the equities market and interest rates. While plenty of high-yield opportunities exist, investors must always consider the safety of their dividend and the total return potential of their investment. It is not uncommon for a struggling company to suspend high-yielding dividends and subsequently result in precipitous share price declines. TheStreet Ratings' stock rating model views dividends favorably, but not so much that other factors are disregarded. Our model gauges the relationship between risk and reward in several ways, including: the pricing drawdown as compared to potential profit volatility, i.e. how much one is willing to risk in order to earn profits?; the level of acceptable volatility for highly performing stocks; the current valuation as compared to projected earnings growth; and the financial strength of the underlying company as compared to its stock's valuation as compared to its stock's performance. These and many more derived observations are then combined, ranked, weighted, and scenario-tested to create a more complete analysis. The result is a systematic and disciplined method of selecting stocks. As always, stock ratings should not be treated as gospel — rather, use them as a starting point for your own research. The following pages contain our analysis of 3 stocks with substantial yields, that ultimately, we have rated "Sell."...

Click to view a price quote on AMTG.

Click to research the Real Estate industry.

Santarus President & CEO Gerald Proehl Honored As San Diego Ernst & Young Entrepreneur Of The Year 2013 In Life Sciences

Mon, 17 Jun 2013 07:30:00 EDT

Santarus, Inc. (NASDAQ:SNTS) today announced that Gerald T. Proehl, president and chief executive officer, received the Ernst & Young Entrepreneur Of The Year ® 2013 award for the Life Sciences category in the San Diego region. Ernst & Young’s Entrepreneur Of The Year is a prestigious business award that recognizes the significant contributions of entrepreneurs who inspire others with their vision, leadership and achievement.

After a successful career in sales and marketing at Hoechst Marion Roussel, Inc., Mr. Proehl joined Santarus in 1999 and became president, chief executive officer and director in 2002. He was the driving force at Santarus to build a positive corporate culture focused on five core values: Teamwork, Ownership, Productivity, Integrity and Quality. Under Mr. Proehl’s leadership, Santarus has built a portfolio of five commercial products and a robust product development pipeline. The company’s strong financial performance and success in its clinical programs has led to the creation of significant shareholder value. ...

Click to view a price quote on SNTS.

Click to research the Drugs industry.

Stocks Under $10 Weekly Summary

Fri, 14 Jun 2013 16:33:57 EDT

During an up-and-down week for stocks, we used the volatility to build up one of our model portfolio positions.

To read the entire article, you must be a member. Click here to become a member.

AstraZeneca And Bristol-Myers Squibb To Present New Data At American Diabetes Association 73rd Scientific Sessions®

Fri, 14 Jun 2013 09:00:00 EDT

AstraZeneca (NYSE: AZN) and Bristol-Myers Squibb Company (NYSE: BMY) announced today that 33 abstracts on the companies’ research in diabetes have been accepted for presentation at the 73rd Scientific Sessions ® of the American Diabetes Association (ADA) in Chicago, June 21-25. The data include studies from five marketed products as well as dapagliflozin, an investigational compound in the U.S., currently approved for use in the European Union, Australia, New Zealand and Mexico. In addition to blood glucose control, studies presented at the meeting examine impact on cardiovascular risk factors such as weight and blood pressure, which are important to overall disease management in people with diabetes.

“The AstraZeneca and Bristol-Myers Squibb Alliance will present data on a broad, versatile portfolio including Onglyza, Kombiglyze XR, Symlin, Byetta and Bydureon, as well as the investigational compound dapagliflozin,” said John Yee, MD, MPH, vice president, head of Medical Affairs, AstraZeneca/Bristol-Myers Squibb U.S. Diabetes Alliance. “The diversity of data reflects our joint commitment to researching and delivering innovative medicines and treatment options to help patients overcome the burdens of diabetes.” ...

Click to view a price quote on AZN.

Click to research the Drugs industry.

Sudan Embassy In DC Reacts To Situation Between Sudan And South Sudan

Thu, 13 Jun 2013 19:39:53 EDT

WASHINGTON, June 13, 2013 /PRNewswire-USNewswire/ -- The Embassy of the Republic of the Sudan in Washington DC would like to state the following in regard to the situation between Sudan and South Sudan in the wake of Sudan's announcement of the suspension of the cooperation agreement between the two countries, including shutting down of the oil pipeline.

1. The decision was taken only after the Sudanese government exhausted all bilateral means to ensure South Sudan respects the concluded agreements by stopping support for rebel movements and withdraws forces from six locations within the Sudanese territories. ...

ALCO Stores, Inc. Reports Operating Results For First Quarter Ended May 5, 2013

Thu, 13 Jun 2013 16:43:27 EDT

ABILENE, Kan., June 13, 2013 (GLOBE NEWSWIRE) -- ALCO Stores, Inc. (Nasdaq:ALCS), which specializes in providing a superior selection of essential products for everyday life in small-town America, today announced operating results for its first quarter ended May 5, 2013.

Net sales from continuing operations during the first quarter of fiscal 2014 increased 0.9% to $117.5 million, compared to $116.5 million in the first quarter of fiscal 2013. Same-store sales, excluding fuel centers, decreased 2.2% to $112.4 million during the first quarter of fiscal 2014. ...

Click to view a price quote on ALCS.

Click to research the Retail industry.

Capstone Turbine Announces Fourth Quarter And Fiscal Year 2013 Operating Results

Thu, 13 Jun 2013 16:15:00 EDT

Best Annual Performance in Company's History

Record Revenue of $127.6 Million for Fiscal 2013 ...

Click to view a price quote on CPST.

Click to research the Industrial industry.

Restoration Hardware Holdings, Inc. Reports Record First Quarter Fiscal 2013 Financial Results

Thu, 13 Jun 2013 16:06:00 EDT

Restoration Hardware Holdings, Inc. (NYSE: RH) today announced financial results for the first quarter ended May 4, 2013.

First Quarter Highlights Net revenues increased 38% on top of an 18% increase for the same period last year Comparable store sales increased 41% on top of 26% growth for the same period last year Direct revenues increased 38% on top of a 20% increase for the same period last year Adjusted operating income increased to $4.6 million from an operating loss of $0.6 million for the same period last year; GAAP operating income of $0.5 million from an operating loss of $2.1 million for the same period last year Adjusted net income increased to $2.3 million from a net loss of $1.3 million for the same period last year; GAAP net loss of $0.2 million from a net loss of $3.7 million for the same period last year Adjusted diluted earnings per share reached $0.06; GAAP diluted earnings per share of $0.00 ...

Click to view a price quote on RH.

Click to research the Retail industry.

Peerless Systems Announces Results For The Quarter Ended April 30, 2013

Thu, 13 Jun 2013 16:05:00 EDT

STAMFORD, Conn., June 13, 2013 (GLOBE NEWSWIRE) -- Peerless Systems Corporation (Nasdaq:PRLS) today reported financial results for its first fiscal quarter that ended April 30, 2013.

First Quarter Results ...

Click to view a price quote on PRLS.

Click to research the Wholesale industry.

WEX Extends Its Existing Fuel-Price Risk Management Program

Thu, 13 Jun 2013 16:05:00 EDT

WEX Inc. (NYSE: WEX), a leading provider of corporate payment solutions, announced today that it has extended its existing fuel-price risk management program through the fourth quarter of 2014.

On June 7, 2013, the Company purchased instruments to cover a portion of its anticipated domestic fuel-price-related earnings exposure for the second, third and fourth quarters of 2014. At this time, WEX has hedged approximately: 60% of its second-quarter 2014 exposure, 40% of its third-quarter 2014 exposure and 20% of its fourth-quarter 2014 exposure. Going forward, the Company intends to hedge approximately 60% of its domestic fuel-price-related earnings exposure in every quarter on a rolling basis. ...

Click to view a price quote on WEX.

Click to research the Diversified Services industry.